Login / Signup

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.

William S WeintraubDeepak L BhattZugui ZhangSarahfaye DolmanWilliam E BodenAdam P BressBrandon K BellowsCatherine G DeringtonSephy PhilipPhillippe Gabriel StegMichael MillerEliot A BrintonTerry A JacobsonJean Claude TardifChristie M BallantynePaul Kolm
Published in: Journal of the American Heart Association (2023)
URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • open label
  • double blind
  • randomized controlled trial
  • patient reported outcomes
  • phase iii
  • ionic liquid
  • placebo controlled
  • study protocol